Recent studies have converged on the overlap of GLP|GIP|glucagon receptor stimulant therapies and DA neurotransmission. While GLP agonists are increasingly employed for addressing type 2 diabetes, their potential https://declanhgbs036594.pages10.com/new-gcgr-agonists-and-da-modulation-a-relative-overview-76845894